A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)
Caribou Biosciences, Inc. is advancing CB-010, a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19, for the treatment of refractory Systemic Lupus Erythematosus (SLE). The market for SLE therapies is growing, driven by the increasing prevalence of autoimmune diseases and the need for effective treatments for refractory cases. However, the competitive landscape includes established therapies and emerging biologics, necessitating a robust differentiation strategy. The withdrawal of the trial due to strategic pipeline prioritization indicates a potential shift in focus towards oncology programs, which may impact investor confidence and future funding for autoimmune indications.
Indication: Systemic Lupus Erythematosus
Modality: cell therapy
Target: CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cells
Sponsor: Caribou Biosciences, Inc.
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 03, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cells
View original source fields
Condition raw: Systemic Lupus Erythematosus, Lupus, Lupus Erythematosus, Lupus Nephritis
Condition normalized: Systemic Lupus Erythematosus, Lupus, Lupus Erythematosus, Lupus Nephritis
Modality raw: cell therapy
Modality normalized: cell therapy
Target raw: CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cells
Target normalized: CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cells